CAP
For many years, the pharmaceutical industry has been waiting for human cells to produce their therapeutic proteins with high yields and activities.
The bottlenecks of current protein production like unsatisfying yields, inauthentic glycosylation, inefficient sialylation, reduced serum half-life or potential immunogenicity of the therapeutic material are overcome by using CEVEC´s unique and proprietary CAP Technology.
CAP cell line for stable expression of biopharmaceuticals offers significant advantages:
- Stable and high expression of human proteins
- Human-like post-translational modifications
- Growth in suspension in serum-free chemically defined medium
- High cell density
- Non-tumor origin, immortalized by a function not oncogenic in human
- Easily accessible, ethically accepted source of origin
- Fast and easy cell line development
- Stable growth parameters in different types of bioreactors
- Suited as well for vaccine production
- Complete cell source and cell line development documentation
With this at hand, our customers around the world are able to outstandingly cope with the exciting task of supplying today´s therapeutic markets with the best biopharmaceuticals possible: safe, easy and efficient:
